AMANTA Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Amanta Healthcare reported a strong Q2 FY27 with 17% YoY revenue growth to INR83.1 crore and 22% YoY EBITDA growth to INR18 crore, maintaining a healthy EBITDA margin of 21.6% despite raw material volatility . The company commissioned SteriPort Line 3, increasing capacity by ~75%, which is expected to ramp to full utilization by late November 2026 . A 10.8 MW captive solar plant is delivering structural cost savings of ~INR9 crore annually . The balance sheet has strengthened with debt/equity down to ~1.1x, and the company has a clear 2-year roadmap of 20%+ revenue CAGR and 25%+ EBITDA margins . The SVP facility, focused on inhalation and ophthalmic products, is expected to be commissioned in Q1 FY28 and is a key future growth driver, though management conservatively guides only INR16 crore revenue from it in FY28 . Key risks include polymer price volatility and regulatory timelines for product approvals. Overall, the earnings call conveyed a positive and confident outlook, backed by clear growth drivers and financial discipline.
Management Tone
- Prepared Remarks: Good — The prepared remarks were confident and forward-looking, highlighting clear drivers: SteriPort Line 3 commissioning, a 10.8 MW captive solar plant delivering INR9 crore in annual savings, debt reduction, a 20+ product pipeline, and explicit 2-year guidance for 20%+ revenue CAGR and 25%+ EBITDA margi
- Q&A Session: Good — The Q&A was substantive, with analysts probing capacity utilization, margins, debt, market share, and the SVP pipeline . Management responded directly with quantified data (e.g., 95-97% utilization, ~6% SteriPort market share, 25-30 cr licensing revenue) and provided a transparent, if cautious, vie
Revenue Growth Drivers
- SteriPort Line 3 capacity expansion and ramp-up
- Captive solar plant reducing power costs
- Product mix shift towards higher-value therapies (onco, critical care, anesthesia)
Growth vs Margin Focus
Management has a clear 2-year target of 20%+ revenue CAGR and 25%+ EBITDA margins . They are investing in capacity expansion (SteriPort, SVP) for growth, while simultaneously focusing on cost efficiencies (solar, automation) and product mix improvement to expand margins .
About Amanta Healthcare Limited
Amanta Healthcare Limited (AMANTA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.